Oramed Pharmaceuticals Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oramed Pharmaceuticals Inc. on May 21, 2010. The report discloses a corporate governance event regarding the appointment of a new member to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance data.
Material Changes
On May 21, 2010, the Company appointed Dr. Michael Berelowitz, MD, as a member of the Board of Directors, effective June 1, 2010. Dr. Berelowitz is currently the Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit at Pfizer, Inc. The Company has not yet determined if he will serve on any specific board committees. His remuneration will be an annual fee consistent with other non-executive directors.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items beyond the director appointment.
Key Facts for Investor Verification
- Dr. Michael Berelowitz joins the Board of Directors effective June 1, 2010.
- Dr. Berelowitz brings experience from Pfizer, Inc., specifically in clinical development and medical affairs.
- His committee assignments have not yet been determined.
- His compensation will align with the annual fee structure for other non-executive directors.